Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rauno A. Naves"'
Autor:
Milja Belik, Arttu Reinholm, Pekka Kolehmainen, Jemna Heroum, Sari Maljanen, Eda Altan, Pamela Österlund, Larissa Laine, Olli Ritvos, Arja Pasternack, Rauno A. Naves, Alina Iakubovskaia, Alex-Mikael Barkoff, Qiushui He, Johanna Lempainen, Paula A. Tähtinen, Lauri Ivaska, Pinja Jalkanen, Ilkka Julkunen, Laura Kakkola
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionMutations occurring in the spike (S) protein of SARS-CoV-2 enables the virus to evade COVID-19 vaccine- and infection-induced immunity.MethodsHere we provide a comprehensive analysis of humoral and cell-mediated immunity in 111 healthcare
Externí odkaz:
https://doaj.org/article/523052bbfb674ef28047590dedb58f43
Autor:
Arttu Reinholm, Sari Maljanen, Pinja Jalkanen, Eda Altan, Sisko Tauriainen, Milja Belik, Marika Skön, Anu Haveri, Pamela Österlund, Alina Iakubovskaia, Arja Pasternack, Rauno A. Naves, Olli Ritvos, Simo Miettinen, Hanni K. Häkkinen, Lauri Ivaska, Paula A. Tähtinen, Johanna Lempainen, Anu Kantele, Laura Kakkola, Ilkka Julkunen, Pekka Kolehmainen
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-13 (2024)
Abstract Background Vaccinations against the SARS-CoV-2 are still crucial in combating the ongoing pandemic that has caused more than 700 million infections and claimed almost 7 million lives in the past four years. Omicron (B.1.1.529) variants have
Externí odkaz:
https://doaj.org/article/752162c32e034fc183b27e8432303dc4
Autor:
Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, Ravi Kant, Petja Salminen, Riku Fagerlund, Sanna Mäki, Anu Haveri, Tomas Strandin, Lauri Kareinen, Jussi Hepojoki, Suvi Kuivanen, Lev Levanov, Arja Pasternack, Rauno A. Naves, Olli Ritvos, Pamela Österlund, Tarja Sironen, Olli Vapalahti, Anja Kipar, Juha T. Huiskonen, Ilona Rissanen, Kalle Saksela
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Here the authors describe a small antibody-like protein that can prevent infection by diverse SARS-CoV-2 variants in cell culture and in mice that were intranasally treated with this inhibitor before or shortly after being exposed to the virus.
Externí odkaz:
https://doaj.org/article/326654b56d2c4bd89b56074f0855fd2f
Autor:
Milja Belik, Pinja Jalkanen, Rickard Lundberg, Arttu Reinholm, Larissa Laine, Elina Väisänen, Marika Skön, Paula A. Tähtinen, Lauri Ivaska, Sari H. Pakkanen, Hanni K. Häkkinen, Eeva Ortamo, Arja Pasternack, Mikael A. Ritvos, Rauno A. Naves, Simo Miettinen, Tarja Sironen, Olli Vapalahti, Olli Ritvos, Pamela Österlund, Anu Kantele, Johanna Lempainen, Laura Kakkola, Pekka Kolehmainen, Ilkka Julkunen
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving thr
Externí odkaz:
https://doaj.org/article/8ed36691f37b46e1b815126d4476c537
Autor:
Milja, Belik, Pinja, Jalkanen, Rickard, Lundberg, Arttu, Reinholm, Larissa, Laine, Elina, Väisänen, Marika, Skön, Paula A, Tähtinen, Lauri, Ivaska, Sari H, Pakkanen, Hanni K, Häkkinen, Eeva, Ortamo, Arja, Pasternack, Mikael A, Ritvos, Rauno A, Naves, Simo, Miettinen, Tarja, Sironen, Olli, Vapalahti, Olli, Ritvos, Pamela, Österlund, Anu, Kantele, Johanna, Lempainen, Laura, Kakkola, Pekka, Kolehmainen, Ilkka, Julkunen
Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3a6d3a9167320494a4d3ec0d4ed7a24f
http://hdl.handle.net/10138/344286
http://hdl.handle.net/10138/344286
Autor:
Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, Petja Salminen, Ravi Kant, Riku Fagerlund, Anu Haveri, Tomas Strandin, Lauri Kareinen, Jussi Hepojoki, Lev Levanov, Arja Pasternack, Rauno A. Naves, Olli Ritvos, Pamela Österlund, Tarja Sironen, Olli Vapalahti, Anja Kipar, Juha T. Huiskonen, Ilona Rissanen, Kalle Saksela
The emergence of the SARS-CoV-2 Omicron variant capable of escaping neutralizing antibodies emphasizes the need for prophylactic strategies to complement vaccination in fighting the COVID-19 pandemic. Nasal epithelium is rich in the ACE2 receptor and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e74811f49ed4a374d136c5d4502172
https://doi.org/10.21203/rs.3.rs-1196079/v1
https://doi.org/10.21203/rs.3.rs-1196079/v1
Autor:
Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, Ravi Kant, Petja Salminen, Riku Fagerlund, Sanna Mäki, Anu Haveri, Tomas Strandin, Lauri Kareinen, Jussi Hepojoki, Suvi Kuivanen, Lev Levanov, Arja Pasternack, Rauno A. Naves, Olli Ritvos, Pamela Österlund, Tarja Sironen, Olli Vapalahti, Anja Kipar, Juha T. Huiskonen, Ilona Rissanen, Kalle Saksela
Publikováno v:
bioRxiv
BioRxiv
BioRxiv
SUMMARYThe recent emergence of novel SARS-CoV-2 variants capable of efficiently escaping neutralizing antibodies emphasizes the need for prophylactic strategies to complement vaccination in fighting the COVID-19 pandemic. Nasal epithelium is rich in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd85234534486633e766b228fd1994d